Cognitive impairment and cortical degeneration in neuromyelitis optica

Annals of Neurology

Volumn 73, Issue 1, 2013, Pages 65-76

  Saji, Etsuji ^a   Arakawa, Musashi ^a   Yanagawa, Kaori ^a   Toyoshima, Yasuko ^a   Yokoseki, Akiko ^a   Okamoto, Kouichirou ^a   Otsuki, Mika ^b   Akazawa, Kohei ^a   Kakita, Akiyoshi ^a   Takahashi, Hitoshi ^a   Nishizawa, Masatoyo ^a   Kawachi, Izumi ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; EXCITATORY AMINO ACID TRANSPORTER 2; GLIAL FIBRILLARY ACIDIC PROTEIN;

AGE DISTRIBUTION; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMYELINATION; HUMAN; IMMUNOREACTIVITY; JAPANESE; MEDICAL RECORD REVIEW; MENINGITIS; MICROGLIA; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AQUAPORIN 4; ASIAN CONTINENTAL ANCESTRY GROUP; ASTROCYTES; CEREBRAL CORTEX; COGNITION DISORDERS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROMYELITIS OPTICA;

EID: 84873342813     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23721     Document Type: Article

References (48)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
5. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009; 73: 1628-1637.
6. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999; 53: 1705-1710.
7. Rocca MA, Agosta F, Mezzapesa DM, et al. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 2004; 62: 476-478.
8. Yu CS, Lin FC, Li KC, et al. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 2006; 27: 1009-1015.
9. Yu C, Lin F, Li K, et al. Pathogenesis of normal-appearing white matter damage in neuromyelitis optica: diffusion-tensor MR imaging. Radiology 2008; 246: 222-228.
10. Rao SM, Leo GJ, Bernardin L, Unverzagt F,. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
11. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (pt 4): 1089-1104.
12. Trapp BD, Stys PK,. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
13. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846.
15. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (pt 7): 1450-1461.
16. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130 (pt 5): 1194-1205.
17. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130 (pt 5): 1224-1234.
18. Liu G, Amin S, Okuhama NN, et al. A quantitative evaluation of peroxidase inhibitors for tyramide signal amplification mediated cytochemistry and histochemistry. Histochem Cell Biol 2006; 126: 283-291.
19. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
20. Patti F, Amato MP, Trojano M, et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009; 15: 779-788.
21. Sartori E, Edan G,. Assessment of cognitive dysfunction in multiple sclerosis. J Neurol Sci 2006; 245: 169-175.
22. Brown ES,. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009; 1179: 41-55.
23. Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477-493.
24. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-2912.
25. Blanc F, Zephir H, Lebrun C, et al. Cognitive functions in neuromyelitis optica. Arch Neurol 2008; 65: 84-88.
26. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68: 603-605.
27. Feuillet L, Reuter F, Audoin B, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007; 13: 124-127.
28. Potagas C, Giogkaraki E, Koutsis G, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci 2008; 267: 100-106.
29. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112 (pt 1): 133-146.
30. Popescu BF, Parisi JE, Cabrera-Gomez JA, et al. Absence of cortical demyelination in neuromyelitis optica. Neurology 2010; 75: 2103-2109.
31. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007; 254: 1212-1220.
32. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-2197.
33. Geurts JJ, Barkhof F,. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008; 7: 841-851.
34. Lassmann H, van Horssen J,. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 2011; 585: 3715-3723.
35. Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Ann Neurol 2011; 69: 445-454.
36. Dutta R, McDonough J, Chang A, et al. Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients. Brain 2007; 130 (pt 10): 2566-2576.
37. Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003; 126 (pt 8): 1755-1766.
38. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
39. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109: 1245-1250.
40. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134 (pt 7): 1914-1924.
41. Beyer AM, Wandinger KP, Siebert E, et al. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings. Clin Neurol Neurosurg 2007; 109: 926-930.
42. Haase CG, Schmidt S,. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica. Neurosci Lett 2001; 307: 131-133.
43. Lalive PH, Menge T, Barman I, et al. Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 2006; 67: 176-177.
44. Chou CH, Chou FC, Tourtellotte WW, Kibler RF,. Devic's syndrome: antibody to glial fibrillary acidic protein in cerebrospinal fluid. Neurology 1984; 34: 86-88.
45. Gomez-Isla T, Price JL, McKeel DW Jr, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491-4500.
46. Harris JA, Devidze N, Verret L, et al. Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 2010; 68: 428-441.
47. Stranahan AM, Mattson MP,. Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer's disease. Neural Plast 2010; 2010: 108190.
48. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999; 122 (pt 7): 1341-1348.